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Kidney ischemic/reperfusion (I/R) injury is the main cause of acute kidney injury (AKI) involving renal function deterioration,
renal architecture damage, and inflammation.)is conditionmay lead to kidney fibrosis with epithelial tomesenchymal transition
(EMT) and myofibroblast formation. Inhibition of chronic effects of kidney I/R injury may provide effective strategies for treating
AKI and chronic kidney diseases (CKDs). Chlorogenic acid (CGA) is recognized as a powerful antioxidant, with anti-in-
flammatory and antifibrotic properties in many conditions. However, the effect of CGA on kidney I/R injury has not been
elucidated yet. Kidney I/R injury was performed on male Swiss background mice (I/R group, n= 5, 3-4months, 30–40 g) which
underwent bilateral renal pedicles clamping for 30minutes and then were euthanized on day three after operation.)ree groups of
I/R were treated with 3 different doses of CGA intraperitoneally for 2 days: 3.5 (I/R +CGA1 group), 7 (I/R +CGA2 group), and 14
(I/R +CGA3 group) mg/kg of body weight. Tubular injury was quantified based on Periodic Acid-Schiff staining, while reverse
transcriptase PCR (RT-PCR) was performed to quantify mRNA expression of TGF-β1, vimentin, SOD-1, TLR-4, TNF-α, NF-κB
and MCP-1. Immunohistochemical staining was done to quantify proliferating cell nuclear antigen (PCNA), myofibroblast
(α-SMA), SOD-1 and macrophage (CD68) number. Kidney I/R demonstrated tubular injury and increased inflammatory
mediator expression, macrophage number, and myofibroblast expansion. Meanwhile, histological analysis showed lower tubular
injury with higher epithelial cell proliferation in CGA-treated groups compared to the I/R group. RT-PCR also revealed sig-
nificantly lower TGF-β1 and vimentin mRNA expressions with higher SOD-1 mRNA expression. CGA-treated groups also
demonstrated a significantly lower macrophage and myofibroblast number compared to the I/R group. )ese findings associated
with lower mRNA expression of TLR-4, TNF-α, NF-κB, and MCP-1 as inflammatory mediators in CGA groups. I/R +CGA3
represented the highest amelioration effect among other CGA-treated groups. CGA treatment attenuates kidney I/R injury
through reducing inflammation, decreasing myofibroblast expansion, and inducing epithelial cells proliferation.
1. Introduction
Acute kidney injury (AKI) incidence has increased in the last
two decades. AKI incidence reached 550 per 100,000 in
population in 2003 [1]. In hospitals, the incidence ranges
from 2% to 7%, and 5 to 10% in intensive care units (ICU)
[2]. Epidemiological data identified different causes of AKI
between developed and developing countries. In the de-
veloped countries, most AKI patients are elderly, while,
predominantly, patients with AKI in developing countries
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are younger populations with prerenal conditions as the
main cause [3].
Kidney ischemic/reperfusion (I/R) injury is the main
cause of AKI. )is condition has high morbidity and
mortality, involving high costs for the treatment. Kidney I/R
injury is also seen as a risk factor for chronic kidney disease
(CKD) [4]. Kidney I/R injury, characterized by reduction
and loss of renal blood flow (stenosis), is followed by
reperfusion. Hypoxia induces epithelial cell injury and ap-
optosis, which are the main consequence of hypoxia [5].
Hypoxia causes cell injury and dysfunction with failure of
the Na+-K+ ATPase pump and increases intracellular cal-
cium ions, thus producing cell death and oxidative stress [6].
Epithelial cell proliferation and regeneration occur after
injury [7]. Tubular epithelial cells undergo epithelial to
mesenchymal transition (EMT) or dedifferentiation. )e
surviving epithelial cells will replace apoptotic cells after AKI
[8]. However, it is known that AKI with kidney I/R injury
might lead to CKDs. In most cases of AKI, EMT type II after
kidney I/R injury plays an important role in renal fibro-
genesis with incomplete regeneration and leads to interstitial
fibrosis [9]. Furthermore, reperfusion itself exaggerates re-
active oxygen species (ROS) production, causing more se-
vere injury after hypoxia [10].
I/R injury also exaggerates metabolic imbalance that
leads to inflammation [11]. During I/R injury, the kidneys
produce Toll-like receptors-2 and -4 (TLR-2 and TLR-4),
thus inducing sterile inflammation. TLRs activation
produces upregulation of proinflammatory mediators
such as TNF-α, MCP-1, IL-8, IL-6, IL-1β, and TGF-β.
Cytokines and chemokines induce infiltration of mac-
rophages [5]. TGF-β plays a role in the fibrotic cascade
and induces fibroblast proliferation, inhibits collagen
deposition, and stimulates collagen production, fibro-
nectin, and proteoglycan [12]. Fibroblast activation
changes the cell phenotype to become myofibroblasts
with α-SMA marker expression [13]. TGF-β is also im-
portant for protecting epithelial cells from sublethal
injury [14]; however, overstimulation to fibroblasts and
epithelial cells produces accumulation of an extracellular
matrix and leads to interstitial fibrosis [15]. In chronic
CKD conditions, kidney fibrosis produces progressive
and irreversible renal function deterioration [12].
Chlorogenic acid (CGA) is a polyphenol substance
containing caffeic and quinic acid [16] which are found in
many vegetable products [17]. It is also found in green coffee.
It has many positive effects, and one of them is reducing I/R
injury in many organs with its anti-inflammation effects
such as inhibiting TNF-α and IL-6 activation and reducing
NF-κB expression [18, 19]. CGA also plays an important role
as an antioxidant substance through eliminating free radicals
[20, 21] and promoting antifibrotic [22] effects. CGA
treatment attenuated hepatic ischemic/reperfusion injury in
rat due to its antioxidant effects [23]. However, the effects of
CGA on kidney I/R injury have not been elucidated yet. )is
study aimed to elucidate the effects of CGA on kidney I/R
injury and demonstrate the renoprotective effects of CGA on
kidney I/R injury, especially in tubular injury, inflammation,
and fibrosis mechanism.
2. Materials and Methods
2.1. Animal Subjects and Kidney Ischemic/Reperfusion (IR)
Injury Model. Swiss background mice (male, n� 25, 3-
4months, 20–30 grams body weight) were used for this study.
Mice were maintained according to the standard laboratory
conditions with the provision of diet and water ad libitum and
12-hour light and dark cycle cages. )is study had been
approved by the Ethical Committee of the Faculty of Med-
icine, Public Health and Nursing, Universitas Gadjah Mada,
with the reference number of KE/FK/1066/EC/2017. Bilateral
renal pedicles clamping was performed to induced kidney IR
injury based on previously published methods [24]. Briefly,
the mice were anesthetized with sodium pentobarbital 0.1ml/
10 g body weight. After that, the abdomen was opened. Next,
both renal pedicles were visualized, clamped with a non-
traumatic vascular clamp for 30minutes, and then removed.
Sham operation (SO group, n� 5) procedure was used for the
control group with only opening the mice’s abdomen without
renal pedicles clamping. Chlorogenic acid (CGA) (Sigma
Aldrich, C3878) was administered through intraperitoneal
injection daily, based on the previous results in rat [23]. We
converted the dose according to the conversion factor of rat
(200 gr/0.2 kg) to mouse (20 gr/0.02 kg) based on the body
weight, which was 0.14 [25]. )en, the formula used for dose
quantification was (dose in rat (mg/kg)×BW of rat (0.2 kg)×
conversion factor (0.14))/BW of mouse (0.02 kg).)e doses of
the rat were 2.5, 5, and 10mg/kg BW, which were equal to 3.5,
7, and 14mg/kg BW based on the formula. Mice were divided
into the following groups: SO group with NaCl 0.9% in-
traperitoneal injection; I/R group (n� 5); I/R group with CGA
dose 3.5mg (I/R+CGA1 group, n� 5), dose 7mg (I/R+CGA2
group, n� 5), and dose 14mg (I/R+CGA3 group, n� 5)/kg of
body weight (BW). On the following day after the operation,
the mice were injected with CGA.Mice were euthanized at day
3 after the operation.
2.2. Euthanizing and Kidney Harvesting. Mice were anes-
thetized with intraperitoneal injection of sodium pento-
barbital (0.1ml/10 g body weight). After opening the
abdomen and thorax, perfusion of the organ was done via
the left ventricle using 0.9% NaCl. Kidneys were harvested,
and then, the right kidney was placed into RNA preservation
solution for RNA extraction and the left kidney was fixated
in normal buffer formalin (NBF) solution for 24 hours and
then used for paraffin making.
2.3. Histological Analysis and Immunohistostaining.
Paraffin-embedded sections with 4 μm thickness were used
for basic staining and immunohistochemical (IHC) staining.
Paraffin sections were deparaffinized and rehydrated using
serial solutions of xylene and alcohol and then stained with
Periodic Acid-Schiff (PAS) to determine and quantify the
tubular injury score. For IHC staining, deparaffinized and
rehydrated steps were followed by antigen retrieval using
heating in citrate buffer pH 6, blocking peroxidase using
H2O2 3% in PBS solution, and then blocking nonspecific
antigen using background sniper (Star Trek IHC kit, BioCare
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Medical). Afterwards, the slides were incubated with
α-smooth muscle actin (α-SMA) (1 : 400, Sigma, A2547),
CD68 (1 : 400, Abcam, ab125212), proliferating cell nuclear
antigen (PCNA) (1 : 200, Abcam, ab29), and super oxide
dismutase-1 (SOD-1) (1 :100, Bioss, bs-10216R) as the 1st
antibodies for overnight incubation in 4°C and then provided
with appropriate 2nd antibody Trekkie Universal Link, Tre-
kAvidin-HRP, and diaminobenzidine-tetrahydrochloride
(DAB) (Biocare Medical®). )e α-SMA antibody immuno-staining was used for measuring myofibroblast expansion,
CD68 antibody for counting macrophage, and proliferating
cell nuclear antigen (PCNA) for assessing epithelial cell
proliferation in the sample kidneys. Later, the quantification
wasmeasured by counting the positive staining signal from 15
fields for each sample with 400x magnification using ImageJ
software. SOD-1 immunostaining was used to localize SOD-1
expression in the tissue.
2.4. Tubular Injury Score. Tubular injury score was assessed
by PAS staining and was determined using a semi-
quantitative scoring system in 15 fields for each specimen
with 200x magnifications. )e variables of scoring were as
follows: (1) tubular atrophy and dilatation, (2) loss of brush
border, (3) accumulation of inflammatory cells, and (4)
intraluminal cast. Otherwise, the scale of injury was from 0
to 4: score 0: normal condition; score 1: mild (injury <25%);
score 2: moderate (injury 25–50%); score 3: severe (injury
50–75%); and score 4: extensive damage (injury >75%).
2.5. Reverse Transcriptase PCR (RT-PCR). RNA was
extracted using Genezol solution (Genezol, Cat. no.
GZR100), followed by the RNA concentration quantifi-
cation using nanodrop ReverTra Ace® (Toyobo, Japan,Cat. no. TRT-101), and random primers (Toyobo, Japan,
Cat. no. 3801) were used in synthesizing the cDNA and
then conducting reverse transcriptase PCR (RT-PCR)
using Master Mix (Go Taq green) for assessing the ex-
pression of the following genes: (1) Toll-like receptor-4/
TLR-4 (forward 5′-GGGCCTAAACCCAGTCTGTTTG-
3′, reverse 3′-GCCCGGTAAGGTCCATGCTA-5′); (2)
monocyte chemoattractant protein-1/MCP-1 (forward 5′-
GGCATCACAGTCCGAGTCACAC-3′, reverse 3′-CTA-
CAGACAACC-ACCTCAAGCACTTCTGTAG-5′); (3)
vimentin (forward 5′-CGGAAAGTGGAATCCTTGCA-
3′, reverse 5′-CACATCGATCTGGACATGCTG-3′); (4)
tumor necrosis factor-α/TNF-α (forward 5′-GCCTCT-
TCTCATTCCTGCTTG-3′, reverse 3′-CTGATGAGAGG-
GAGGCCATT-5′); (5) nuclear factor-κB/NF-κB (forward
5′-GCGTACACATTCTGGGGAGT-3′, reverse 3′-ACCG-
AAGCAGGAGCTATCAA-5′); (6) super oxide dismutase-
1/SOD-1 (forward 5′-AGCATTCCATCATTGGCCGTA-
3′, reverse 3′-TTTCCACCTTTGCCCAAGTCA-5′); and
(7) GAPDH (forward 5′-TTGCTGTTGAAGTCGCAG-
GAG-3′, reverse 3′-TGTGTCCGTCGTGGATCTGA-5′)
were used as reference. )e gene expressions were quanti-
fied using densitometry analysis (ImageJ software), and the
GAPDH gene was used to normalize the gene expressions
(house-keeping gene).
2.6. Statistical Analysis. Statistical analysis was done using
SPSS 22 for Windows (IBM, Chicago). )e distribution of
the data was priorly determined using the Shapiro–Wilk test
and presented as mean± standard error measurement
(SEM) to be analyzed by parametric tests using one-way
ANOVA. For multiple comparisons, the data were then
examined using the post hoc LSD test. )e level of statistical
significance was p< 0.05.
3. Results
3.1. CGA Treatment Attenuated Kidney Injury and Tubular
Injury and Increased Epithelial Cell Proliferation after Kidney
I/R Injury. Kidney I/R injury demonstrated kidney injury
with higher tubular injury and creatinine level. Damaged
renal architecture in the IR group was demonstrated with
tubular cell apoptosis, tubular dilatation and atrophy, brush
border loss, intraluminal cast formation, and macrophage
infiltration (Figure 1). Quantification of tubular injury
showed higher scores in the I/R group compared to the SO
group.
Amelioration of renal architecture was shown in the
CGA group, which was demonstrated by significantly lower
tubular injury scores in I/R CGA2 and I/R +CGA3 groups
compared to the I/R group. CGA treatment also induced
proliferation of epithelial cells. Quantification of PCNA IHC
staining as a key proliferation marker revealed significantly
higher proliferation of epithelial cells in the I/R group
compared to SO. Furthermore, I/R +CGA2 and I/R +CGA3
groups had higher proliferation of epithelial cell number
compared to the I/R group. I/R +CGA3 had the highest
number of proliferating epithelial cells. )ese findings as-
sociated with amelioration of kidney function in CGA-
treated groups, as shown with significantly lower serum
creatinine levels in the IR +CGA3 group compared to the IR
group.)e IR group also demonstrated higher mesenchymal
marker, vimentin and profibrotic marker, and TGF-β1.
Meanwhile, CGA-treated groups represented lower
vimentin and TGF-β1 mRNA expressions compared to the
I/R group. IR +CGA3 had significantly lower vimentin and
TGF-β1 mRNA expressions compared to the IR group.
3.2. CGA Attenuated Myofibroblast Expansion and Upregu-
lated SOD-1 Expression. I/R injury induced myofibroblast
expansion as shown by a significantly higher myofibroblast
number in the I/R group compared to the SO group
(Figures 2(a) and 2(c)). Meanwhile, there were significantly
lower myofibroblast numbers in the I/R +CGA2 and
I/R +CGA3 groups compared to the I/R group. Myofibro-
blast expansions might be associated with oxidative stress
and antioxidant enzyme reduction. Immunostaining of
SOD-1, an antioxidant enzyme, showed positive staining in
tubular epithelial cells in the SO group (Figure 2(b)). I/R
groups demonstrated reduction of positive signaling com-
pared to SO. )is finding was confirmed with RT-PCR of
SOD-1 mRNA which showed significantly lower SOD-1
mRNA expression in the I/R group compared to SO. CGA-
treated groups had higher SOD-1 mRNA expression;
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however, only the I/R+CGA3 group had significantly higher
expression compared to the I/R group. Immunostaining of
SOD-1 also demonstrated positive staining in tubular epithelial
cells of the I/R+CGA3 group. Quantification of TLR4 and
MCP-1 mRNA expressions confirmed significantly higher
numbers in the I/R group compared to SO. RT-PCR revealed
only the I/R+CGA3 group had significantly lower TLR-4 and
MCP-1 mRNA expressions compared to the I/R group.
3.3. CGA Treatment Induced Lower Inflammation and
Myofibroblast Expansion. RT-PCR also revealed in-
crement of inflammation mediators in the IR group. We
confirmed higher mRNA expression of NF-κB, a tran-
scription factor, and TNF-α, an inflammatory mediator.
On the other hand, CGA-treated groups demonstrated
lower mRNA expression of NF-κB and TNF-α; however,
only the I/R + CGA3 group revealed significantly higher
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Figure 1: (a) Representative pictures of PAS staining in all groups. )e SO group had normal histology of kidney tissue with brush border.
)e IR group had tubular injury characteristics with dilatation and brush-border loss (white arrow). (b) Immunostaining of PCNA showed
positive staining in epithelial cells’ nuclei (black arrows). (c, d). Quantification of tubular injury score and PCNA-positive cell number
showed attenuation of tubular injury which associated with the increased number of proliferating epithelial cells in CGA-treated groups
(especially IR +CGA3 group). (e) Creatinine level measurement showed reduction in the IR +CGA3 group. (f ) Reverse transcriptase-PCR
(RT-PCR) analysis of vimentin (mesenchymal marker) and TGF-β1 (profibrotic factor). )e IR+CGA3 group demonstrated significantly
lower vimentin and TGF-β1 mRNA expressions with the IR group. ∗p< 0.05 vs. SO group; ∗∗p< 0.01 vs. IR group; ∗∗∗p< 0.001 vs. SO group.
#p< 0.05 vs. IR group; ##p< 0.01 vs. IR group; ###p< 0.001 vs. IR group.
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mRNA expression compared to the IR group (Figures 3(a)
and 3(b)). IHC staining confirmed higher macrophage
infiltration after kidney I/R injury as shown by the higher
macrophage number in the I/R group compared to the SO
group. Lower inflammatory mediator expression in CGA
groups associated with the lower macrophage number
compared to the I/R group. We found dose-dependent
effect of CGA treatment in lowering the macrophage
number and inflammation. CGA treatment with the
highest dose had the lowest macrophage number and
inflammatory mediator expression.
4. Discussion
)is study highlighted the role of CGA in attenuating kidney
I/R injury progression through attenuating tubular injury,
inflammation, and myofibroblast formation. Kidney I/R in-
jury leads to AKI and induces tubular injury. Regeneration of
the kidneys after injury is characterized by dedifferentiation,
proliferation, and migration of survived tubular epithelial
cells. )ese cells replace the dead cells [8]. )is condition
changes the phenotype of the epithelial cells, from cuboid or
columnar shape to squamous-like mesenchymal cells. )is
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Figure 2: (a) Representative pictures of α-SMA immunostaining for myofibroblast marker. Positive staining is shown in interstitial areas
(white arrow). (b) Representative pictures of SOD-1 immunostaining. Positive staining is shown in epithelial cells in SO, meanwhile
reduction in the IR group.)e IR +CGA3 group demonstrated positive staining in epithelial cells. (c) Quantification of the myofibroblast
number showed reduction of the numbers in CGA-treated groups, especially the IR +CGA3 group. (d) Reverse transcriptase-PCR (RT-
PCR) analysis of SOD-1. )e IR +CGA3 group demonstrated significantly higher SOD-1 mRNA expression compared to the IR group.
(e) Reverse transcriptase-PCR (RT-PCR) analysis of inflammatory markers (TLR-4 and MCP-1). )e IR +CGA3 group demonstrated
significantly lower MCP-1 and TLR-4 mRNA expressions with the IR group. ∗p< 0.05 vs. SO group; ∗∗p< 0.01 vs. SO group; ∗∗∗p< 0.001
vs. SO group. #p< 0.05 vs. IR group; ##p< 0.01 vs. IR group; ###p< 0.001 vs. IR group.
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process is known as epithelial-mesenchymal transition (EMT)
[26, 27]. EMT is characterized by the reduction of epithelial
marker expression, such as E-cadherin, and upregulation of
mesenchymal marker expression, such as vimentin [26]. It
seems that regeneration after I/R injury may induce EMT. In
this study, we revealed an improvement of tubular injury in
the CGA group associated with not only increased tubular
proliferation but also reduction of EMT, as shown by the
reduction of vimentin and TGF-β1 mRNA expressions.
Vimentin is known as a key mesenchymal marker, but it also
represents the differentiation process. Higher expression of
vimentin after ischemia might indicate the ongoing re-
generation process [27]. However, it is known that AKI with
kidney I/R injury might lead to CKDs. EMT type II after
kidney I/R injury also plays a role in renal fibrogenesis with
incomplete regeneration and leads to interstitial fibrosis [9].
In our immunohistochemical staining, it appeared that CGA
treatment might ameliorate tubular injury, inducing renal
epithelial cell proliferation; however, it preserved those epi-
thelial cells while inhibiting the EMT process that leads to
fibrosis.
Kidney I/R injury also induces inflammation and ROS
production which then activates TGF-β1 directly or in-
directly [28, 29], causing complementary activation and
endothelial injury [5, 30]. Transforming growth factor-β1
(TGF-β1) may promote EMTand fibrosis [31, 32]. ROS itself
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Figure 3: (a, b) Reverse transcriptase-PCR (RT-PCR) analysis of NF-κB and TNF-α mRNA expressions. )e IR +CGA3 group dem-
onstrated significantly lower NF-κB and TNF-α mRNA expressions compared to the IR group. (b) Representative pictures of CD68
immunostaining for macrophage marker. Positive staining is shown in interstitial areas (black arrow). (c) Quantification of the macrophage
number showed reduction of the numbers in CGA-treated groups, especially the IR +CGA3 group. (d) Representative pictures of CD68
immunostaining for demonstrating macrophage infiltration (black arrows). ∗p< 0.05 vs. SO group. #p< 0.05 vs. IR group.
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has been known to have different actions in epithelial and
interstitial cells. ROS induces apoptosis of epithelial cells,
while promoting proliferation of interstitial cells [33]. )is
may cause an increased number of myofibroblasts in the
interstitial area after kidney I/R injury.
Our study confirmed that CGA might not only induce
proliferation and regeneration of epithelial cells but also may
reduce the expansion of myofibroblasts. )ese findings are
associated with an elevation of antioxidant enzyme, SOD-1.
)e CGA-treated groups revealed upregulation of SOD-1
mRNA expression.)is result suggested that the antioxidant
effects of CGA may be beneficial in inducing epithelial cell
proliferation and inhibiting interstitial cells proliferation.
CGA has been known as having antioxidant effects through
eliminating free radicals. It has an R-OH sequence that binds
to free radicals [19]. ROS itself induces TGF-β1 activation in
the interstitial area [29].
Our study also demonstrated upregulation of TGF-β1
mRNA expression and increase in the myofibroblast
number after I/R injury. Increased myofibroblast forma-
tion in kidney I/R injury may be associated with TGF-β1
upregulation as a main regulator of fibrosis and the EMT
process [31, 34]. TGF-β1 upregulation may occur tempo-
rarily in AKI for regeneration induction, while the upre-
gulation if prolonged can induce CKD and kidney fibrosis
[35]. )ese conditions produce inflammation, fibroblast
expansion, extracellular matrix deposition, and fibrosis as
final pathways [5]. TGF-β1 upregulation occurs signifi-
cantly 3 hours after injury and continues to 14 days after
injury [36, 37]. Our results demonstrated significantly
lower TGF-β1 mRNA expression in the I/R +CGA3 group
compared to the I/R group. )is finding demonstrated
CGA decreased TGFβ1 mRNA expression in a dose-de-
pendent manner. CGA treatment has been reported
ameliorating liver fibrosis in the carbon tetrachloride-
(CCl4-) induced hepatic fibrosis model. )e reduction of
fibrosis was associated with reduction of TGF-β1 and
α-SMA protein level expressions [22]. Similar results were
also shown by one study that used CGA treatment for
attenuating liver fibrosis in common bile duct ligation.
Reduction of fibrosis was also associated with reduction of
collagen I and collagen III, TGF-β1, and α-SMA expres-
sions [8]. Furthermore, CGA also downregulated TGF-β1
expression in a subtotal nephrectomy model [38].
Hypoxia after I/R injury leads to upregulation of the NF-
κB transcription factor [39] which then induces TGF-β
upregulation [40], inflammation cytokines, such as TNF-α,
IL-1β, and IL-6 [41], CCL and CXCL subfamily [42], and
iNOS [30]. TGF-β production can be stimulated by in-
flammation cytokines in tubular epithelial cells [43]. Fo-
cusing on inflammation responses after kidney I/R injury,
we investigated TLR-4 signaling and its downstream path-
ways. Kidney I/R injury induced upregulation of TLR-4 and
its downstream signaling and NF-κB, TNF-α, and MCP-1
mRNA expressions (Figure 2), which are associated with
macrophage infiltration as shown by the higher macrophage
number in the I/R group. Meanwhile, CGA treatment at-
tenuated inflammation through reducing TLR-4 signaling
(NF-κB, TNF-α, and MCP-1) and the macrophage number.
Dead cells release damage-associated molecular patterns
(DAMPs) such as heat shock protein HMGB1 which binds
to TLR-4 and inducing inflammatory cytokines such as
TNF-α and IL-1β [44]. Increased chemokine from epithelial
cells, monocyte and macrophage, and dendritic cells induces
inflammatory cells migration such as macrophage, neu-
trophil, and lymphocyte via CCR1 receptor interaction [42].
ROS and adhesion molecules such as ICAM-1 and P-selectin
from endothelial cells also increase leucocyte and neutrophil
infiltration [30]. Inflammatory cells produce inflammatory
chemokines, TNF-α, IL-1β, and IL-6 [4, 45], and ROS [46],
which then exacerbate TGF-β production.
TLR-4 increases at 24 hours in endothelial cells and then
at 24 hours from epithelial cells. It is sustained for 3–5 days,
mainly from tubular epithelial cells [47]. CGA is a phyto-
chemical substance with many functions, such as anti-in-
flammation [48, 49], antioxidant, and antiapoptosis effects
[48]. CGA reduces TNF-α protein level expression and
mRNA expression of iNOS and COX-2. CGA inhibits re-
lease of high mobility group box 1 (HMGB-1) to extracel-
lular, thus inhibiting TLR-4 expression upregulation and
NF-κB nuclear translocation [50]. CGA also impedes TLR-4
expression through inhibiting IκB phosphorylation which is
associated with NF-κB activation [51]. Anti-inflammatory
effect of CGA might be in a dose-dependent manner as
shown by significantly lower TLR-4 and MCP-1 mRNA
expressions in the CGA+ I/R3 group, but not in other
groups. Based on the conversion dose method, our dose was
similar to the study by Yun et al. (2012); however, they used
the liver I/R injury model [23]. TLR-4 signaling activation
induces NF-κB activation and then produces inflammatory
mediators [4], especially MCP-1 [52]. MCP-1 promotor has
two binding sites for NF-κB, which increases in the first
30minutes after kidney I/R injury [53]. Many cells produce
MCP-1, such as neutrophils, endothelial cells, and mac-
rophages [54]. Based on the results of our study, we as-
sumed that reduction of MCP-1 expression might be due to
reduction of TLR-4 expression and activation. Although
there are many pathways which induce MCP-1 expression
after I/R injury, activation of JNK may be associated with
MCP-1 expression in I/R injury. Pharmacologically, JNK
blockade reduced MCP-1 expression [55]. Tubular epi-
thelial cells also express CD40 ligands that interact with
Cd154, which activate MAPK and produce MCP-1 and Il-8
in tubular epithelial cells. )is process signals and triggers
p38 and ERK1/2 of MAPK [56]. Exploring those signaling
pathways in renoprotective effects of CGA on kidney I/R
injury may provide better understanding of the beneficial
underlying mechanism.
MCP-1 is themain attractant for macrophage recruitment
in I/R injury [4]. Types of macrophage depend on the time
aspect after I/R injury. During the first 3 days of the injury,M1
macrophage will be activated and then M2 macrophage is
activated on day 7 after I/R injury. M1 macrophage releases
proinflammatory cytokines due to ROS. Meanwhile, M2
macrophage may play an important role in repair process [5].
Here, we reported that CGA treatment-reduced macrophage
infiltration with a significantly lower macrophage number in
the I/R +CGA2 and I/R+CGA3 groups compared to the I/R
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group (Figure 2). )e SO group demonstrated positive
staining of macrophages which represented resident mac-
rophages in the kidneys. Lower macrophage numbers in
CGA-treated groups might be associated with anti-in-
flammation effects of CGA. Recently, research showed the
CGA-attenuatedMCP-1 and CD68 expressions in the hepatic
steatosis model in mice [57].
5. Conclusion
Here, we demonstrated renoprotective effects of CGA on
kidney I/R injury through reducing inflammatory mediators
and macrophage infiltration, while also reducing EMT and
myofibroblast formation.
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